ANTRONOTTECREMA BARRIERA VISO

Informazioni principali

  • Nome commerciale:
  • ANTRONOTTECREMA BARRIERA VISO
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • ANTRONOTTECREMA BARRIERA VISO
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • DISPOSITIVI NON COMPRESI NELLE CLASSI PRECEDENTI - ALTRI

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Stato dell'autorizzazione:
  • N
  • Data dell'autorizzazione:
  • 20-03-2010
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

3-12-2018

January 11, 2019: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement

January 11, 2019: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement

January 11, 2019: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

3-12-2018

January 16, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement

January 16, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement

January 16, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

24-9-2018

November 1, 2018: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee & Drug Safety and Risk Management Advisory Committee Meeting Announcement

November 1, 2018: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee & Drug Safety and Risk Management Advisory Committee Meeting Announcement

November 1, 2018: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee & Drug Safety and Risk Management Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

19-9-2018

October 24-25, 2018: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement

October 24-25, 2018: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement

October 24-25, 2018: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

13-9-2018

October 10, 2018: Meeting of the Oncologic Drugs Advisory Committee

October 10, 2018: Meeting of the Oncologic Drugs Advisory Committee

October 10, 2018: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

9-8-2018

Dermatologic and Ophthalmic Drugs Advisory Committee Roster

Dermatologic and Ophthalmic Drugs Advisory Committee Roster

This page contains the DODAC roster, which lists the current members and the current number of vacancies for the committee.

FDA - U.S. Food and Drug Administration

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

12-7-2018

Oncologic Drugs Advisory Committee Roster

Oncologic Drugs Advisory Committee Roster

This page contains the ODAC roster, which lists the current members and the current number of vacancies for the committee.

FDA - U.S. Food and Drug Administration

5-6-2018

Camellia sinensis (green tea) extract

Camellia sinensis (green tea) extract

Safety advisory - potential risk of harm to the liver

Therapeutic Goods Administration - Australia

2-6-2018

Solve Botanical Slimming capsules

Solve Botanical Slimming capsules

Safety advisory - Solve Botanical Slimming capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

31-5-2018

Dolutegravir

Dolutegravir

Safety advisory - new study suggests possible risk of birth defects

Therapeutic Goods Administration - Australia

23-5-2018

Hypnotic poisom capsules

Hypnotic poisom capsules

Hypnotic poisom capsules safety advisory

Therapeutic Goods Administration - Australia

17-5-2018

JAGUAR 30000 capsules

JAGUAR 30000 capsules

Safety advisory

Therapeutic Goods Administration - Australia

15-5-2018

Nonprescription Drugs Advisory Committee

Nonprescription Drugs Advisory Committee

he Nonprescription Drugs Advisory Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.

FDA - U.S. Food and Drug Administration

14-5-2018

Lishou Strong Slimming capsule

Lishou Strong Slimming capsule

Safety advisory

Therapeutic Goods Administration - Australia

9-5-2018

SLIM BODY Advanced capsules

SLIM BODY Advanced capsules

Safety advisory

Therapeutic Goods Administration - Australia

7-5-2018

Pulmonary-Allergy Drugs Advisory Committee Roster

Pulmonary-Allergy Drugs Advisory Committee Roster

This page contains the Pulmonary-Allergy Drugs Advisory Committee roster, which lists the current members and the current number of vacancies for the committee.

FDA - U.S. Food and Drug Administration

19-4-2018

Fluad trivalent influenza vaccine

Fluad trivalent influenza vaccine

Safety advisory - risk to patients with latex allergy

Therapeutic Goods Administration - Australia

18-4-2018

ViaGro 500mg Male Enhancement capsules

ViaGro 500mg Male Enhancement capsules

Safety advisory

Therapeutic Goods Administration - Australia

17-4-2018

Gold Viagra 9800mg capsules

Gold Viagra 9800mg capsules

Safety advisory

Therapeutic Goods Administration - Australia

17-4-2018

LIPRO Dietary capsules

LIPRO Dietary capsules

Safety advisory

Therapeutic Goods Administration - Australia

9-4-2018

Vegetal Vigra capsules

Vegetal Vigra capsules

Safety advisory

Therapeutic Goods Administration - Australia

9-4-2018

Black Ant King tablets

Black Ant King tablets

Safety advisory

Therapeutic Goods Administration - Australia

19-3-2018

Arthrem capsules

Arthrem capsules

Safety advisory – potential risk of harm to the liver

Therapeutic Goods Administration - Australia

15-3-2018

Duro-K 600 mg potassium chloride tablets

Duro-K 600 mg potassium chloride tablets

Advisory – lead content may exceed regulatory guidelines

Therapeutic Goods Administration - Australia

27-2-2018

Therakos Cellex Photopheresis System

Therakos Cellex Photopheresis System

Update: Therakos Cellex Photopheresis System Safety advisory – risk of blood clots

Therapeutic Goods Administration - Australia

3-2-2015

New director at the DHMA

New director at the DHMA

On 1 February 2015, Anne-Marie Vangsted, Acting Head of Division, took up the position as Director with responsibility for supervision at the Danish Health and Medicines Authority. The new position as director was created as part of our action plan aimed at modernising the supervisory function, in which Anne-Marie Vangsted has played a key role since we presented the plan on 15 September 2014.

Danish Medicines Agency

14-1-2019

Submissions received: Benzocaine: proposed advisory statements for medicines

Submissions received: Benzocaine: proposed advisory statements for medicines

Submissions received on the Benzocaine: proposed advisory statements for medicines have been published

Therapeutic Goods Administration - Australia

14-1-2019

Consultation: Benzocaine: proposed advisory statements for medicines

Consultation: Benzocaine: proposed advisory statements for medicines

The TGA is seeking comments on proposed new required label statements for medicines containing benzocaine. Closing date: 16 October 2018

Therapeutic Goods Administration - Australia

23-11-2018

Presentations have been posted for the November 15, 2018 Patient Engagement Advisory Committee meeting. #PEAC2018 Read more:  https://go.usa.gov/xPHxf   #FDA #MedicalDevice

Presentations have been posted for the November 15, 2018 Patient Engagement Advisory Committee meeting. #PEAC2018 Read more: https://go.usa.gov/xPHxf  #FDA #MedicalDevice

Presentations have been posted for the November 15, 2018 Patient Engagement Advisory Committee meeting. #PEAC2018 Read more: https://go.usa.gov/xPHxf  #FDA #MedicalDevice

FDA - U.S. Food and Drug Administration

13-11-2018

Check out the #PEAC2018 agenda, webcast information, and meeting materials for Thursday’s Patient Engagement Advisory Committee meeting on  http://FDA.gov : https://go.usa.gov/xPf9n  #DigitalHealthpic.twitter.com/1DCieYB33v

Check out the #PEAC2018 agenda, webcast information, and meeting materials for Thursday’s Patient Engagement Advisory Committee meeting on http://FDA.gov : https://go.usa.gov/xPf9n  #DigitalHealthpic.twitter.com/1DCieYB33v

Check out the #PEAC2018 agenda, webcast information, and meeting materials for Thursday’s Patient Engagement Advisory Committee meeting on http://FDA.gov : https://go.usa.gov/xPf9n  #DigitalHealth pic.twitter.com/1DCieYB33v

FDA - U.S. Food and Drug Administration

9-11-2018

ACM meeting statement, Meeting 11, 4 October 2018

ACM meeting statement, Meeting 11, 4 October 2018

The Advisory Committee on Medicines meeting statement for Meeting 11 is now available

Therapeutic Goods Administration - Australia

8-11-2018

There's only 1 week until the 2018 Patient Engagement Advisory Committee meeting. Join the @US_FDA on Nov 15 to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries.pic.twitter.com/WkDNnXqm

There's only 1 week until the 2018 Patient Engagement Advisory Committee meeting. Join the @US_FDA on Nov 15 to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries.pic.twitter.com/WkDNnXqm

There's only 1 week until the 2018 Patient Engagement Advisory Committee meeting. Join the @US_FDA on Nov 15 to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries. pic.twitter.com/WkDNnXqmbw

FDA - U.S. Food and Drug Administration

7-11-2018

ACMD meeting statement, Meeting 43, 11 October 2018

ACMD meeting statement, Meeting 43, 11 October 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

17-10-2018

Save the date & Join the @US_FDA’s  Patient Engagement Advisory Committee on Nov 15th to discuss  patient-generated health data from sources like social media, activity  trackers, and patient-driven registries. Learn more:  https://go.usa.gov/xPRau  #Digi

Save the date & Join the @US_FDA’s Patient Engagement Advisory Committee on Nov 15th to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries. Learn more: https://go.usa.gov/xPRau  #Digi

Save the date & Join the @US_FDA’s Patient Engagement Advisory Committee on Nov 15th to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries. Learn more: https://go.usa.gov/xPRau  #DigitalHealth #PEAC2018 pic.twitter.com/NU61Snpxxw

FDA - U.S. Food and Drug Administration

21-9-2018

#FDA announces the 2nd Patient Engagement Advisory Committee meeting on November 15th at the Hilton Hotel in Gaithersburg, MD.

#FDA announces the 2nd Patient Engagement Advisory Committee meeting on November 15th at the Hilton Hotel in Gaithersburg, MD.

#FDA announces the 2nd Patient Engagement Advisory Committee meeting on November 15th at the Hilton Hotel in Gaithersburg, MD.

FDA - U.S. Food and Drug Administration

14-9-2018

Federal Register Notice: #FDA Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee. Nominations are due by November 5, 2018. For more information, click here:  https://go.usa.g

Federal Register Notice: #FDA Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee. Nominations are due by November 5, 2018. For more information, click here: https://go.usa.g

Federal Register Notice: #FDA Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee. Nominations are due by November 5, 2018. For more information, click here: https://go.usa.gov/xPgW5  #MedicalDevice

FDA - U.S. Food and Drug Administration

14-9-2018

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here:  https://go.usa.gov/xPgWa  #MedicalDevice

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here: https://go.usa.gov/xPgWa  #MedicalDevice

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here: https://go.usa.gov/xPgWa  #MedicalDevice

FDA - U.S. Food and Drug Administration

14-9-2018

Federal Register Notice: #FDA Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee. Nominations are due by November 5, 2018. For more information, click here: https://

Federal Register Notice: #FDA Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee. Nominations are due by November 5, 2018. For more information, click here: https://

Federal Register Notice: #FDA Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee. Nominations are due by November 5, 2018. For more information, click here: https://go.usa.gov/xPgDd 

FDA - U.S. Food and Drug Administration

7-9-2018

 2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

Enpr-EMA will hold its tenth annual workshop on 7-8 June 2018 at EMA. The workshop brings relevant stakeholders together to discuss requirements, barriers and opportunities for the conduct of high-quality clinical studies in children. The overall theme of this year’s workshop will be a ‘holistic approach to paediatric research’. Highlights of this year’s workshop include: i) short perspectives of the various stakeholders involved in paediatric research (patient/young people advisory groups, research netw...

Europe - EMA - European Medicines Agency

4-9-2018

ACM meeting statement, Meeting 10, 2 August 2018

ACM meeting statement, Meeting 10, 2 August 2018

The Advisory Committee on Medicines meeting statement is now available

Therapeutic Goods Administration - Australia

31-8-2018

ACV meeting statement, Meeting 9, 1 August 2018

ACV meeting statement, Meeting 9, 1 August 2018

Advisory Committee on Vaccines meeting statement is now available

Therapeutic Goods Administration - Australia

30-8-2018

Consultation: Referral of proposed amendment to the current Poisons Standard to the meeting of the ACMS, March 2019

Consultation: Referral of proposed amendment to the current Poisons Standard to the meeting of the ACMS, March 2019

Advisory Committee on Medicines Scheduling to consider upscheduling of modified release paracetamol to 'Pharmacist Only'. Closing date 31 October 2018

Therapeutic Goods Administration - Australia

30-8-2018

Modified release paracetamol

Modified release paracetamol

Advisory Committee on Medicines Scheduling to consider upscheduling of modified release paracetamol to 'Pharmacist Only'

Therapeutic Goods Administration - Australia

28-8-2018

ACCM meeting statement, Meeting 18, 8 December 2017

ACCM meeting statement, Meeting 18, 8 December 2017

Advisory Committee on Complementary Medicines Meeting 18 meeting statement

Therapeutic Goods Administration - Australia

28-8-2018

ACCM meeting statement, Meeting 19, 22 March 2018

ACCM meeting statement, Meeting 19, 22 March 2018

Advisory Committee on Complementary Medicines Meeting 19 meeting statement

Therapeutic Goods Administration - Australia

27-8-2018

Somavert (Pfizer Europe MA EEIG)

Somavert (Pfizer Europe MA EEIG)

Somavert (Active substance: Pegvisomant ) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5684 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000409/T/0087

Europe -DG Health and Food Safety

7-8-2018

ACMD meeting statement, Meeting 40, 12 April 2018

ACMD meeting statement, Meeting 40, 12 April 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

7-8-2018

ACMD meeting statement, Meeting 41, 28 June 2018

ACMD meeting statement, Meeting 41, 28 June 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

24-7-2018

ACV meeting statement, Meeting 8, 30 May 2018

ACV meeting statement, Meeting 8, 30 May 2018

Advisory Committee on Vaccines meeting statement

Therapeutic Goods Administration - Australia

4-7-2018

ACM meeting statement, Meeting 9, 31 May - 1 June 2018

ACM meeting statement, Meeting 9, 31 May - 1 June 2018

Advisory Committee on Medicines

Therapeutic Goods Administration - Australia

2-7-2018

Statutory advisory committee vacancies

Statutory advisory committee vacancies

We are seeking expressions of interest for vacancies on the Statutory advisory committees. Closing date: 31 July 2018

Therapeutic Goods Administration - Australia

29-6-2018

ACV meeting statement, Meeting 7, 28 March 2018

ACV meeting statement, Meeting 7, 28 March 2018

Advisory Committee on Vaccines meeting statement

Therapeutic Goods Administration - Australia

20-6-2018

Monitoraggio della Spesa Farmaceutica Nazionale e Regionale (gennaio / febbraio 2018) - provvisorio (20/06/2018)

Monitoraggio della Spesa Farmaceutica Nazionale e Regionale (gennaio / febbraio 2018) - provvisorio (20/06/2018)

L'Agenzia Italiana del Farmaco rende disponibile l'estratto sul Monitoraggio della Spesa Farmaceutica Nazionale e Regionale (gennaio / febbraio 2018).

Italia - AIFA - Agenzia Italiana del Farmaco

25-5-2018

ACV meeting statement, Meeting 6, 7 February 2018

ACV meeting statement, Meeting 6, 7 February 2018

Advisory Committee on Vaccines meeting statement

Therapeutic Goods Administration - Australia

24-5-2018

Consultation:  miconazole and fluconazole: proposed advisory statements for medicines

Consultation: miconazole and fluconazole: proposed advisory statements for medicines

The TGA is seeking comments on the proposed RASML statements for OTC medicines containing miconazole or fluconazole. Closing date: 21 June 2018

Therapeutic Goods Administration - Australia

24-5-2018

Consultation: Sedating antihistamines: proposed additional advisory statements for medicines

Consultation: Sedating antihistamines: proposed additional advisory statements for medicines

The TGA is seeking comments on the proposed RASML statements for OTC medicines containing sedating antihistamines. Closing date: 21 June 2018

Therapeutic Goods Administration - Australia

21-5-2018

Pls RT: 10 Ways to Keep Athletes Safe While in the Sun: WEAR HATS, SUNGLASSES, AND VISORS. Don't forget: May 25 is #DontFryDay  https://loom.ly/Gbg7XBw  #skincancerpic.twitter.com/WAPabvM811

Pls RT: 10 Ways to Keep Athletes Safe While in the Sun: WEAR HATS, SUNGLASSES, AND VISORS. Don't forget: May 25 is #DontFryDay https://loom.ly/Gbg7XBw  #skincancerpic.twitter.com/WAPabvM811

Pls RT: 10 Ways to Keep Athletes Safe While in the Sun: WEAR HATS, SUNGLASSES, AND VISORS. Don't forget: May 25 is #DontFryDay https://loom.ly/Gbg7XBw  #skincancer pic.twitter.com/WAPabvM811

FDA - U.S. Food and Drug Administration

7-5-2018

Conflicts of interest and confidentiality obligations

Conflicts of interest and confidentiality obligations

Guidance for TGA advisory committees has been updated

Therapeutic Goods Administration - Australia